Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 30;5(4):353-68.
doi: 10.3390/ph5040353.

On the regulatory approval pathway of biosimilar products

Jun Wang  1 , Shein-Chung Chow
Affiliations

On the regulatory approval pathway of biosimilar products

Jun Wang et al. Pharmaceuticals (Basel). .

Abstract

Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA has taken the lead in the regulatory approval framework for biosimilar products, and WHO has published guidelines on the evaluation of biosimilars in order to facilitate the global harmonization. Based on EMA and WHO guidelines, many other countries such as Canada, Japan and Korea have also issued their own guidance for evaluating follow-on biologics. The US FDA was authorized to approve follow-on biologics by the BPCI Act passed by the US Congress on March 23, 2010, and has just issued a draft guidance in early 2012. The basic concepts and main principles of approving biosimilars are similar among various nations, notwithstanding some differences in regard to the scope, the choice of reference product, and the data requirement. This article reviews the regulatory approval pathway of biosimilar products in different regions.

PubMed Disclaimer

References

    1. Chow S.C., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence studies. 3rd. Chapman Hall/CRC Press, Taylor & Francis; New York, USA: 2008. Introduction.
    1. Chow S.C., Hsieh T.C., Chi E., Yang J. A comparison of moment-based and probability-based criterial for assessment of follow-on biologics. J. Biopharm. Stat. . 2010;20:31–45. doi: 10.1080/10543400903280308. - DOI - PubMed
    1. McCamish M., Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3:209–217. doi: 10.4161/mabs.3.2.15005. - DOI - PMC - PubMed
    1. WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) WHO; Geneva, Switzerland: 2009.
    1. Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) Health Canada; Ottawa, Canada: 2010.